Announcement on Expected Loss in Performance for 2025
Filed with SSE · · 2 pages · Chinese
Bio-Thera Solutions, Ltd. on 6ix
Earlier from Bio-Thera Solutions
- Announcement on Return of Raised Funds Temporarily Used to Supplement Current Capital
- Announcement on Signing a Project Construction Work Contract by the Wholly-owned Subsidiary and Related Party and Related Party Transactions
- Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization, Production, Supply and Commercialization Agreement with Gedeon Richter Plc. (Richter Gedeon) for BAT2206 (Ustekinumab) Injection
- Announcement on Voluntary Disclosure of Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Hikma Pharmaceuticals USA Inc. for BAT2206 (Ustekinumab) Injection
- Announcement on Voluntary Disclosure of Progress in Milestone Payment Received for Signing Authorization License and Commercialization Agreement with Sandoz AG for BAT1706 (Bevacizumab) Injection
Later from Bio-Thera Solutions
- Announcement on Changing Sponsor Representative
- Announcement on Voluntary Disclosure of Execution of a License, Manufacturing, Supply, and Commercialization Agreement with Avalon Pharma Regarding BAT3306 (Pembrolizumab) Injection
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on Marketing Authorization Approval of Gotenfia (Golimumab Injection) by European Medicines Agency (EMA)
- STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi
Follow Bio-Thera Solutions into a list and get an email when it puts out news.
Follow Bio-Thera Solutions